AskBio Doses First Limb-Girdle Muscular Dystrophy Patient
AskBio, a Bayer subsidiary, announced the advancement of its Phase 1/Phase 2 LION-CS101 clinical trial for AB-1003, a gene...
MindRank’s MRANK-106 Gets FDA Clearance for Oncology Trials
MindRank, an AI-driven drug discovery company, has received FDA Investigational New Drug (IND) application clearance for MRANK-106. MRANK-106 is...
Promising Rhenium-186 Obisbemeda GBM Phase 1 Results in Nature Communications
Plus Therapeutics announced positive Phase 1 clinical trial results for Rhenium (¹⁸⁶Re) Obisbemeda in treating recurrent glioblastoma (GBM), published...
Briumvi Data at AAN 2025 Meeting: TG Therapeutics MS Treatment
TG Therapeutics announced upcoming presentations of Briumvi (ublituximab-xiiy) data for relapsing multiple sclerosis (RMS) at the American Academy of...
Givastomig Phase 1b Study Sees Accelerated Progress
I-Mab, a global biotech company, announced the completion of enrollment, ahead of schedule, in the first dose expansion cohort...
BioXcel’s Serenity Trial: At-Home Agitation Treatment
BioXcel Therapeutics has reached 33% enrollment (67 patients) in its 200-patient Phase 3 SERENITY At-Home trial for BXCL501 (dexmedetomidine...
Regeneron and Sanofi: Dupixent® Bullous Pemphigoid Data at AAD
Regeneron and Sanofi announced positive Phase 2/3 trial results for Dupixent (dupilumab) in treating moderate-to-severe bullous pemphigoid (BP), a...
Late-Breaking ESK-001 Phase 2 Data Presented at AAD Meeting
Alumis announced positive 52-week data from the open-label extension of its Phase 2 STRIDE trial for ESK-001, an oral...
Study Shows Increased Cardiometabolic Risk After Switching to Integrase Inhibitors
The AIDS Clinical Trials Group (ACTG) presented data from the REPRIEVE study at the 2025 Conference on Retroviruses and...
aTyr Pharma’s EFZOFITIMOD Shows Promise in Sarcoidosis Treatment
aTyr Pharma’s Phase 3 EFZO-FIT™ study of efzofitimod for pulmonary sarcoidosis received a positive safety review from an independent...